Skip to Content

Lamictal XR Approval History

FDA Approved: Yes (First approved May 29, 2009)
Brand name: Lamictal XR
Generic name: lamotrigine
Dosage form: Extended Release Tablets
Company: GlaxoSmithKline
Treatment for: Seizures

Lamictal XR (lamotrigine) is a once-daily antiepileptic drug indicated as adjunctive therapy for partial onset seizures with or without secondary generalization and primary generalized tonic-clonic seizures in patients 13 years of age or older. Lamictal XR is also indicated for conversion to monotherapy for the treatment of partial onset seizures.

Development History and FDA Approval Process for Lamictal XR

DateArticle
Apr 26, 2011Approval FDA Approves Lamictal XR (Lamotrigine) for Conversion to Monotherapy for Treatment of Partial Seizures in Appropriate Patients
Feb  5, 2010Approval FDA Approves Once-A-Day Lamictal XR as Add-On Epilepsy Therapy for Primary Generalized Tonic-Clonic Seizures

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide